Your donation will make a difference:
Cystic Fibrosis Trust
  • Home
  • /
  • Home
  • /
  • News
  • /
  • UK CF data shows drop in Pseudomonas and need for IVs

UK CF data shows drop in Pseudomonas and need for IVs

Long-term data trends published in the UK Cystic Fibrosis Registry 2018 data report present a mixed picture overall, with drops in the prevalence of Pseudomonas and the proportion of people with CF on at least one course of IV antibiotics, but a widening gap in predicted survival between men and women.

Alongside the drop in Pseudomonas rates, people with CF are staying free from chronic infection for longer, developing chronic infection at an older age. In addition, the targets for the number of people with the bacteria receiving inhaled antibiotics are being met in children (90%) and nearly met in adults (89%).

The median predicted survival age for men is now 51 years, the first time that this figure has been over 50. While the median predicted survival age for women has grown to 44.1, it is 6.9 years lower than the predicted age for men, presenting a growing divide between men and women with cystic fibrosis.

While the average age of death increased by one year in 2018, it shows that half of people with CF who died in 2018 were just 32 years old, or younger.  The latest edition of the annual report also sees a number of new features, including a population pyramid that illustrates the increasing adult CF population over time, and a genotype map of the UK.

Rebecca Cosgriff, Director of Data & Quality Improvement at the Cystic Fibrosis Trust, which maintains the Registry, said: “The UK CF Registry is a vital tool both for snapshots of the picture of health for people with CF in the UK today and to discern emerging trends and patterns. None of this would be possible without the more than 99% of the UK CF population consenting to share their data to support breakthroughs in research and the highest quality of care. 

“This year the UK was the first CF patient registry in the world to report its data for 2018. This is a testament to the dedication of CF teams across the country.”

Get the full story with the full 2018 Registry report or the key findings in the at-a-glance report.

Related content

  • Triple timeline announced by NICE

    Yesterday, NICE announced its planned timelines for assessing the triple combination therapy, with 16 December 2020 the date they expect to publish...

  • A storm is coming!

    The Cystic Fibrosis Trust was delighted to hear that the CF STORM trial has received £1.5m funding from the Government’s National Institute of...

  • UK CF Medical Association's statement on coronavirus

    If you have questions that are not answered in the below please contact our Helpline on While we endeavour to...

  • My summer of CF research

    What sparked your interest in cystic fibrosis? While I was doing my A Levels, I worked as a health care support worker part time. It was my first...